unresectable non-small cell lung cancer
Nov 03, 2017
AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes
AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
